{"disease":{"id":"hepatocellular-carcinoma-hcc","name":"hepatocellular carcinoma hcc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07153783","title":"Interventional AI-Human Collaboration for Liver Tumor Diagnosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":10333,"lead_sponsor_name":"Shengjing Hospital","has_results":false},{"nct_id":"NCT07157085","title":"AI Multitask Model for HCC Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":7000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07368530","title":"Using Machine Learning to Identify Responders to TACE or HAIC for uHCC","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07038863","title":"Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT07156617","title":"A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Xuhua Duan","has_results":false},{"nct_id":"NCT06799468","title":"Validation of the TRAIN-AI for the Risk of HCC Recurrence After Liver Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":1769,"lead_sponsor_name":"European Hepatocellular Cancer Liver Transplant Group","has_results":false},{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06881446","title":"Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without TACE for Advanced HCC with Vascular Invasions","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT06637059","title":"Artificially Intelligent Model for Accurate Detection of HCC","phase":"","overall_status":"COMPLETED","enrollment_count":1092,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT07481032","title":"Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1034,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06774768","title":"Use of Machine-learning Algorithms, Biomarkers and Measures of Quality of Life to Personalize Medical Management of Liver and Heart Transplant Recipients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT07417800","title":"Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06806579","title":"Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT07224750","title":"A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT01761266","title":"A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":954,"lead_sponsor_name":"Eisai Limited","has_results":true},{"nct_id":"NCT06663904","title":"Different Abbreviated MRI for Hepatocellular Carcinoma Diagnosis","phase":"","overall_status":"COMPLETED","enrollment_count":938,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06881433","title":"Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without HAIC for Advanced HCC","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT06842563","title":"Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":900,"lead_sponsor_name":"Singlera Genomics Inc.","has_results":false},{"nct_id":"NCT04539717","title":"FAST (Focused Abbreviated Screening Technique)-MRI Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":820,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT06864195","title":"A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT06923176","title":"Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":704,"lead_sponsor_name":"Zhiyun Yang","has_results":false},{"nct_id":"NCT04639180","title":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":687,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT03412773","title":"A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":684,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT07490262","title":"A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":680,"lead_sponsor_name":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","has_results":false},{"nct_id":"NCT06841185","title":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":656,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT05720195","title":"ALBI and PALBI Scores and HCC Prognosis","phase":"","overall_status":"COMPLETED","enrollment_count":645,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT07469319","title":"Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":617,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT07265271","title":"A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07030842","title":"Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":579,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04523493","title":"Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":530,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT02188901","title":"Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":523,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT06938945","title":"Electronic Symptom Monitoring of Patient-Reported Outcomes Among Patients With Hepatocellular Carcinoma During Immunotherapy (PRIME-HCC): Protocol for a Randomised Controlled Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Wei Xiaoping","has_results":false},{"nct_id":"NCT06639971","title":"Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT07418138","title":"Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":484,"lead_sponsor_name":"Hu Liangshuo","has_results":false},{"nct_id":"NCT02178722","title":"Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT05213637","title":"Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":430,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT07078292","title":"The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT07170345","title":"Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Chinese Academy of Sciences","has_results":false},{"nct_id":"NCT07537946","title":"Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06778317","title":"MSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients with Cirrhosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT06750159","title":"The Use of AKR1B10 for Monitoring Postoperative Recurrence of Hepatocellular Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06739317","title":"SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":398,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT06914648","title":"The Dragon PLC Trial (DRAGON-PLC)","phase":"NA","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"Maastricht University","has_results":false},{"nct_id":"NCT07365930","title":"NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false},{"nct_id":"NCT07120750","title":"Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":332,"lead_sponsor_name":"Shenzhen Third People's Hospital","has_results":false},{"nct_id":"NCT04723004","title":"Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":326,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT07449065","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","phase":"","overall_status":"COMPLETED","enrollment_count":324,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT03236636","title":"The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":312,"lead_sponsor_name":"Beijing Shenogen Biomedical Co., Ltd","has_results":false},{"nct_id":"NCT07381660","title":"SBRT Versus Surgical Resection for Small HCC","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":312,"lead_sponsor_name":"Sun Yat-sen University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}